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Summary Purpose The goal of these studies was to test if
local excess of a normal nucleobase substrate prevents the
toxicity of protracted 5FU exposure used in human cancer
treatment. Methods Messenger RNA expression studies were
performed of 5FU activating enzymes in human colon cancer
cells lines (CaCo-2, HT-29), primary human gingival cells
(HEGP), and normal esophageal and gastric clinical tissue
samples. Excess nucleobase was then used in vitro to protect
cells from 5FU toxicity. Results Pyrimidine salvage pathways
predominate in squamous cells of the gingiva (HEGP) and
esophageal tissue. Excess salvage nucleobase uracil but not
adenine prevented 5FU toxicity in HEGP cells. Pyrimidine
de novo synthesis predominates in columnar Caco-2, HT-29
and gastric tissue. Excess nucleobase adenine but not uracil
prevented 5FU toxicity to Caco-2 and HT-29 cells.
Conclusion The directed application of the normal nucleobase
uracil to the squamous cells of the oral mucosa and palms and
soles together with the delivery of the normal nucleobase ad-
enine to the columnar cells of the GI tract may enable the safe
delivery of higher 5FU dose intensity. These results also sug-
gest a feature of tissue function where squamous cells grow
largely by recycling overlying tissue cell components. Colum-
nar cells use absorbed surface nutrients for de novo growth. A
disruption of this tissue function can result in growth derived
from an underlying nutrient source. That change would also
cause the loss of the region of cell turnover at the tissue sur-
face. Subsequent cell proliferation with limiting nutrient avail-
ability could promote oncogenesis in such initiated tissue.
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Introduction
5-Fluorouracil (5-FU) and its pro-drugs are a component of
the standard therapy for a variety of malignancies. However,
the toxicity, in particular to the gastrointestinal tract and skin
of hands and feet, limits the overall utility of these drugs [1]. 5-
FU rapidly enters the cell using the same facilitated transport
mechanisms as uracil, including the nucleobase transporters
SLC29A2 [2] and SLC22A7 [3]. 5-FU is converted intracellu-
larly to several active metabolites by three routes [4]: the 5-
phosphoribosyl 1-pyrophosphate (PRPP)-mediated conversion
of 5-FU to 5-fluoro-uridine-monophosphate (FUMP) by
orotate phosphoribosyl transferase (OPRT)/Uridine
monophosphate synthetase (UMPS); sequential conversion of
5-FU to FUMP by uridine phosphorylase (UPP1) and uridine
kinase (UCK2), and; the sequential conversion of 5-FU to 5-
fluoro-deoxy-uridine-monophosphate (FdUMP) by thymidine
phosphorylase (TYMP) and thymidine kinase (TK1). The an-
titumor activity results from inhibition of thymidylate synthase
(TS) by FdUMP, as well as from incorporation of 5-FU metab-
olites into RNA and DNA. Only a small part of the 5-FU dose
is activated via these routes, as 80–90 % of the administered
* John P. Ford
jpfordmd@hotmail.com
1 Department of Veterinary and Biomedical Sciences and Center for
Molecular Toxicology and Carcinogenesis, Penn State University,
325 Life Sciences Building, University Park, PA 16802, USA
2 INDIGO Biosciences, Inc., 1981 Pine Hall Road, State
College, PA 16801, USA
3 Mount Nittany Medical Center, 1850 East Park Avenue, State
College, PA 16803, USA
4 Asymmetric Therapeutics LLC, 141 Main St., PO Box J,
Unadilla, NY 13849, USA
Invest New Drugs (2015) 33:1003–1011
DOI 10.1007/s10637-015-0259-x
dose in humans is degraded to 5, 6 dihydrofluorouracil (DHFU)
by dihydropyrimidine dehydrogenase (DPYD).
The toxicity and efficacy of 5-FU is highly variable and is
dependent on the expression and polymorphisms of the detox-
ification and activation enzymes. For example, the Gly213Ala
polymorphism in UMPS/OPRT is predictive of GI toxicity
following 5-FU chemotherapy [5], a finding that may be rel-
evant for the present study. DPYD mutations are associated
with altered 5-FU toxicity (6). The inter-individual differences
in expression of 5-FU metabolism enzymes in addition to
functional protein differences further complicates the predic-
tion of the likelihood of toxicity to 5-FU [6]. In vitro, the
expression of enzymes such as DPYD, TYMS, UCK2, and
UMPS influence sensitivity to 5-FU [7]. The use of oral 5-FU
results in irregular absorption with marked intra- and inter-
individual differences due to the variable activity of DPYD,
especially in the GI tract.
As a result of these concerns, oral 5-FU pro-drugs have
been developed [1, 8]. Three commonly utilized 5-FU
prodrugs are capecitabine (CAP), UFT (ftorafur (FTO) plus
uracil), and S-1 (FTO plus 5-chloro- 2,4-dihydroxypyridine
and potassium oxonate) [1]. CAP is converted into 5-FU in
a three-stage process. In an alternate effort to improve the
therapeutic index of the 5-FU, UFT, a mixture of the FTO
and uracil (U) in molar proportions of 1:4, has been devel-
oped. Uracil, a natural substrate for DPYD, competes with 5-
FU for degradation [9]. Finally, a third alternative to improve
the therapeutic index of 5-FU is S-1, a combination of a FTO
and 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium
oxonate (OXO). CDHP is a potent and reversible inhibitor
of DPYD and OXO is a competitive inhibitor of UMPS.
UFT and S-1 expose the patient systemically to drug compo-
nents, which may alter the therapeutic index of 5FU. Systemic
uracil in UFT may compete for the activation of 5-FU in the
tumor by UPP-1 and decrease anti-tumor activity. OXO in S-1
may also inhibit UMPS in the normal GI tract and decrease the
synthesis of UMP and thus increase the toxicity of 5-FU.
We attempted to prevent the toxicity of 5-FU by a strategy
of applying a non-competitive inhibitor, a normal substrate of
the target enzyme of 5-FU, locally and in excess to the tissue
cell-type subject to toxicity. Using cell culture model systems,
we demonstrate that adenine, but not uracil, is effective and
non-toxic in preventing 5-FU toxicity in the colon cancer cell
lines (Caco-2 and HT-29). Uracil, but not adenine, is effective
at preventing 5-FU toxicity and is itself non-toxic to primary
gingival cells (HGEP). Differences in gene expression of py-
rimidine metabolic enzymes between the tissue types may
explain the differential sensitivity to nucleobase protection
of 5-FU toxicity.
To sustain growth squamous cells of the oropharynyx rely
predominantly on salvage of cell constituents from the over-
lying cells closer to the tissue surface. GI glandular cells rely
predominantly on de novo pyrimidine synthesis from nutrients
in the GI contents. This gene expression pattern difference
paradoxically suggests a fundamental common feature of on-
cogenesis for both squamous and columnar cells of the GI
tract. For normal cells of both tissues there may be a normal
nutrient-driven growth away from the zone of replication at
the epithelial/mesenchymal interface and towards the surface.
When the normal growth directed away from the zone of
replication is inadequate to meet the nutrient requirement of
the tissue, both squamous and glandular cells evoke a nutri-
tional response through neovascularization of the underlying
mesenchymal layer. The consequence for both squamous and
columnar cells is postulated to be growth towards, rather than
away from, the zone of replication. A competition for nutri-
ents and survival could develop at the epithelial/mesenchymal
junction and leads to dysplasia and if sustained oncogenesis.
Taken together, these studies show differential protection of 5-
FU toxicity by nucleobases and also suggest a fundamental
common characteristic of GI epithelial tissue function.
Material and methods
Cell culture Caco-2, obtained from American Type Culture
Collection (ATCC, Manassas, VA), were grown in DMEM
supplemented with 5 ml penicillin (100 UI/ml), streptomycin
(100 μg/ml), 5 ml amphotericin B (250 μg/ml) and 5 % FBS.
Normal human gingival progenitor cells, cryopreserved at P2
(HGEP), were cultured as instructed by the supplier, (Zen-Bio,
Research Triangle Park, NC) using the supplied media and
antibiotics. Cells were seeded into 96-well tissue culture plates
and treated as outlined in the figure legends. Cell viability was
assessed using CellTiter-Glo® Luminescent Cell Viability As-
say following the supplied protocol (Promega Corp., Madison
WI). For experiments where delivery of nucleosides was by
liposomes, Trans-IT TKO (Mirus, Madison WI) was used
following the protocol provided for delivery of siRNA.
Tissue samples After obtaining informed consent, 5 paired
biopsy specimens were obtained during routine upper endos-
copy at the Mount NittanyMedical Center from the squamous
cells lining the esophagus, above the gastroesophageal junc-
tion, as well as from the columnar cells lining the gastric
mucosa, below the gastroesophageal junction. The project
was presented to and approved by the Institutional Review
Board at Mount Nittany Medical Center. One portion of the
biopsy specimens was analyzed in part by microscopy to con-
firm the predicted histology. No sample revealed significant
pathology. The remaining tissue was snap-frozen on dry ice
and subsequently stored at −80 °C until analysis.
Gene expression analysis Total RNA was isolated from the
tissues using TriReagent (Sigma, St. Louis, MO) according to
the manufacturer’s instructions; real time quantitative PCR
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was performed as previously described [10–12]. The total
RNA was reverse transcribed using the ABI High Capacity
cDNA archive kit (Applied Biosystems, Foster City, CA).
Standard curves were made using serial dilutions from pooled
cDNA samples. Real-time polymerase chain reaction (PCR)
was performed in the presence of SYBR green and amplified
on the ABI Prism 7000 Sequence Detection System. The
genes examined and primer sequences are shown in Table 1.
Statistical analysis Differences between treatments were de-
termined using ANOVA followed by Dunnett’s post-hoc test
(JMP 7, SAS Institute, Cary NC). Significant differences were
determined when p<0.05. Non-linear regression and EC50
calculations were performed with Prism 5.0 (GraphPad Soft-
ware, Inc., San Diego, CA).
Results
The levels of various transcripts encoding key enzymes of 5-
FUmetabolism were examined in Caco-2, HEGP, HT-29 cells
as well as human biopsy samples taken from squamous
(esophagus, Eso) and epithelial (gastric tissue, Gas) tissues.
Specifically, those enzymes as part of pyrimidine salvage
(TYMP, UPP1, SLC22A7), DNA replication (TK1, UCK-2,
PRPS, DPYD-1) and de novo nucleotide synthesis (UMPS,
APRT, SLC29A2) pathways (Fig. 1) were examined. Interest-
ingly, when the expression of each gene was examined across
all the samples using hierarchical clustering, the genes orga-
nized into the three ontological pathways (Fig. 1a). The py-
rimidine salvage pathways predominated in the oral and
esophageal samples whereas the replicative and de novo syn-
thesis pathways were expressed at a higher level in the colon
cancer-derived lines. TYMP mRNAwas higher in Eso versus
Gas biopsies and was different in each of the three cell lines
with HEGP showing the highest expression (Fig. 1b). UPP1
expression was similar between Eso and Gas samples, but was
significantly higher in HEGP than in Caco-2 or HT29. A
similar pattern of gene expression was seen for SLC22A7,
although in this instance Caco-2 exhibited higher expression
of this mRNA than did HT-29. TK1 expression was slightly
different between Eso and Gas (p<0.08 with one outlier) sam-
ples and was lower in HEGP relative to Caco-2 and HT-29
(Fig. 1c). Due to high variability, there were no significant
differences in UCK-2 expression, although PRPS and
DPYD-1 mRNA accumulated in HT-29 relative to Caco-2.
For the de novo synthesis transcripts (Fig. 1d), the absolute
mRNA levels were higher for UMPS, APRTand SLC29A2 in
Gas compared to Eso biopsies, but none was significantly
different. UMPS and APRT mRNA levels were lowest in
HEGP progenitor cells.
In view of the fact that gene expression was different be-
tween pyrimidine salvage enzyme transcripts, the sensitivity
to 5-FU and nucleobase competition was examined using
Caco-2 cells to typify the GI tract, comprised predominantly
of epithelial cells, and HGEP cells to represent oral mucosa
squamous epithelial cells. Both Caco-2 and HGEP cells were
treated with various concentrations of 5-FU for 72 h, with
fresh media and 5-FU delivered daily (Fig. 2). The Caco-2
cell line was slightly less sensitive to 5-FU than was HGEP
(EC50 7 versus 2 μM, respectively). Neither cell line exhibited
100 % cell death, even after treatment for 1 week. In fact, in
Caco-2 cultures a population of cells that were resistant to 5-
FU emerged and cell viability increased slightly following
longer-term treatment (data not shown).
The nucleobases adenine (A), orotate (O) and uracil (U)
were examined as inhibitors of the toxic effects of 5-FU. De-
livery of adenine and orotate to Caco-2 cells in aqueous solu-
tion lead to a protection against 5-FU toxicity (Fig. 3). Addi-
tion of uracil to the AO solution negated the cytoprotective
effects seen in Caco-2. In contrast, aqueous delivery of AO to
HGEP cells had no effect in the absence of uracil, but uracil
showed a dose-dependent increase in protection against 5-FU.
Most mammalian cells exhibit low-affinity, equilibrative nu-
cleoside and nucleobase transporters (ENTs, SLC29 family),
while some tissues, typified by liver, small intestine and
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kidney, also exhibit concentrative, sodium-dependent nucleo-
side transport (SLC28 family) [2]. To assess the role of these
transporters on uptake of the nucleobases adenine, orotate and
uracil, liposomes were prepared for delivery into Caco-2 and
HGEP cells. The application of the empty liposomes
themselves reduced 5FU toxicity to the cells but the results
with the application of uracil, adenine and orotate as 5FU
protective agents were similar to those obtained by aqueous
incubation with nucleobases (data not presented). Thus, deliv-
ery of the nucleobases via SLC transporters is unlikely to be
Fig. 1 Expression of mRNA for 5-FU metabolism enzymes. The basal
level of expression of messenger RNA for 5-FU metabolic enzymes in
Caco-2, HT29 and HEGP cells (n=3) as well as esophagus (Eso) and
gastric (Gas) biopsies (5 individuals) was assessed by quantitative RT-
PCR. Data is expressed relative to β-actin. The Esophogus and Gastric
tissues were compared using paired t-test and asterisk denotes a
significant difference between the samples (p<0.05). For the cell lines,
bars with different letters are significantly different from each other
(ANOVA, followed by Tukey’s multicomparison test, p<0.05)
Fig. 2 Sensitivity of Caco-2 and HGEP cells to 5-FU toxicity. Cells were
plated in 96-well plates and allowed to adhere overnight. Subsequently, 5-
FU was dissolved in water and added to media at various concentrations.
Media was changed every day with reapplication of 5-FU. After 72 h, the
cell viability was assessed and is expressed relative to the vehicle control.
(Caco-2, n=3; HGEP, n=4)
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responsible for the differences observed in cytoprotection of
adenine, orotate and uracil from 5FU toxicity. Because of the
relative simplicity of aqueous incubation, the subsequent ex-
periments utilized this method of treatment.
The cytoprotective effect of aqueous delivery of adenine,
orotate and uracil in Caco-2 cells was examined in more detail
(Fig. 4). Adenine at 0.0125 mM through 1.25 mM resulted in
progressively greater cytoprotection against 10 μM 5-FU tox-
icity (Fig. 4a). Addition of orotate (0–1.25 mM) did not atten-
uate 5-FU toxicity produced by adenine. At higher concentra-
tions of adenine (2.5 mM), the addition of orotate at 1.25 mM
may have provided enhanced protection against 5-FU toxicity
in Caco-2 cells. Still higher concentrations of orotate caused
progressively greater abrogation of salvage from 5-FU toxic-
ity (Fig. 4b). As shown in Fig. 4c, the purine nucleoside ino-
sine does not prevent 5-FU toxicity in contrast to the purine
nucleobase adenine. A reversal of AO cytoprotection by uracil
was seen in cells exposed to 10 μM 5-FU (Fig. 4d).
Discussion
Differential expression of the enzymes of de novo synthesis
versus salvage of pyrimidine nucleosides between anatomic
regions may explain the differences in nucleobase specificity
in preventing 5-FU toxicity. The expression of pyrimidine
salvage enzymes, including TYMP, UPP1 and SLC22A7, is
highest in HEGP of oral cavity-derived keratinized squamous
cell tissue. HEGP cells were slightly more sensitive to 5-FU
toxicity and were protected from 5-FU toxicity by uracil that
can be salvaged by TYMP1 to uridine but not by adenine and
orotate, nucleobases involved in de novo pyrimidine synthe-
sis. The esophagus has a simple stratified squamous epithelial
surface without keratin. The esophagus utilizes both salvage
and de novo synthesis, as evidenced by the slightly higher
expression of UMPS, APRT and SLC29A2 relative to the
gingival cell line that has a keratin layer. The increased pro-
liferative enzymes in the distal esophagus are consistent with
tissue stress.
The comprehensive analysis of gene expression in human
GI tract and Caco-2 [13] was reanalyzed to examine 5-FU
metabolic enzymes (data not shown) and illustrated that
Caco-2 cells most closely resemble cells of the colonic epithe-
lium. For the Caco-2 cells of columnar origin, exposure to
adenine showed a significant and dose-dependent protective
effect from 5-FU toxicity. The sensitivity of Caco-2 cells to
adenine cytoprotection may be dependent on the dominant
role of de novo synthesis, in particular UMPS. The mecha-
nism of protection by adenine may be the result of relative
depletion of PRPP by APRT. The Km for PRPP are similar for
APRT (33 μM, [14]) and UMPS (25 μM, [15]), which indi-
cates that in the presence of vast excess adenine relative to 5-
FU, the utilization of PRPP by APRT will be favored. In
addition because of pK difference, the Km of UMPS for
orotate (5.5 μM) is 30-fold lower than that of 5-FU
(190 μM [15]). Thus, with limited PRPP availability endoge-
nously produced orotate will be utilized by UMPS over 5-FU.
The failure of orotate as a monotherapy to prevent 5-FU
toxicity probably relates to two facts: orotate with a negative
charge at neutral pH is poorly taken-up by the cells. Because
of its low Km for UMPS, increased intracellular orotate com-
petes successfully for PRPP and can deplete PRPP and can
cause “purineless” cell death.
Uracil enhanced 5-FU toxicity in Caco-2 cells. This result
may reflect the depletion of ribose-1-phosphate by uracil,
thereby increasing 5-FU concentration available for activation
by UMPS in a cell type significantly dependent on de novo
synthesis of pyrimidine nucleosides. Because of its much
higher Km, uracil competes ineffectively with 5-FU for acti-
vation by UMPS. Taken together, these studies have shown
that differences in gene expression of pyrimidine metabolic
enzymes may explain the differential sensitivity to nucleobase
protection of 5-FU toxicity (see Fig. 5, top panels).
Evidence for a clinical role for uracil protection from 5-FU
toxicity already exists. Systemic uracil is a component of UFT
that is in clinical use and UFT is well-tolerated and, in contrast
to the administration of 5-FU alone, has a very low incidence
of both 5-FU cutaneous toxicity (“hand-foot” syndrome) and
oral stomatitis [9]. Topical uracil has been applied clinically
and has prevented “Hand-Foot” syndrome from 5-FU treat-
ment [16]. Systemic adenine has been used clinically as well
in other contexts. Its unique toxicity, renal stones from the
metabolite 2,8-dihydroxyadenine, is prevented by co-
administration of allopurinol [17]. The dose of adenine re-
quired in the present context is much lower than that cited
(100 mg/kg body weight). A clinical test of topical uracil
Fig. 3 Protection of 5-FU toxicity by aqueous delivery of adenine plus
orotate. Cells were plated in 96-well plates and allowed to adhere
overnight. Subsequently, cells were treated with adenine plus orotate
(2.5 mM each, A/O) or A/O plus uracil (A/O/U) at 1.25 and 2.5 mM in
water. 5-FU was dissolved in water and added to media at 10 μM. Media
was changed every day with reapplication of 5-FU and nucleosides. After
72 h, the cell viability was assessed and is expressed relative to the vehicle
control. (Caco-2, n=3; HGEP, n=4). Within each cell line, bars with
different letters are significantly different from each other (ANOVA,
followed by Tukey’smulticomparison test, p<0.05)
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applied to the mouth to prevent oral stomatitis and, with the
same rationale, oral slow-release adenine to protect the GI
mucosa from the effects of 5-FU treatment would be
reasonable.
Tissue cell-type differences in pyrimidine metabolism,
whether predominantly by salvage or by de novo synthesis,
suggests a common aspect of tissue structure (see Fig. 5, bot-
tom panels) with implications for 5-FU toxicity as well as
oncogenesis. For normal squamous cells in the GI tract, rep-
lication occurs at the epithelial-mesenchymal interface and
growth proceeds towards the surface layer with concomitant
and progressive loss and release of cell components. For glan-
dular cells there is a normal zone of replication at the base of
the crypt that involves aWnt (wingless and Int-1) gradient and
the replicative signal originates with the intestinal
subepithelial myofibroblasts near the muscularis mucosa of
the mesenchyme [18]. Growing normally, epithelial glandular
cells migrate away from the zone of replication towards the
top of the crypt and the predominant de novo nutrient source
in the GI lumen. At the top of the crypt the cells are shed.
As the first layer of epithelial cells for both squamous and
columnar cell types derives nutrition from the mesenchymal
layer below, the normal response of tissue to nutrient stress is a
transient reversal nutrient source, such as likely occurs in
wounding and ontogeny. For both squamous and columnar
cells, persistent nutrient stress causes an activation of HIF1-
alpha. This transcription factor is synthesized in response to
anoxia or lack of glucose and results in a proliferation of new
blood vessels in the underlying mesenchymal layer [19]. With
dysplasia, the site of growth and replication persists. This
results for both squamous and columnar cells in a tissue where
the epithelial layer growth pattern is inverted. Of vital
Fig. 4 Dose–response relationships for adenine (A), inosine (I), uracil
(U) and orotate (O) for protection of Caco-2 cells from 5-FU toxicity.
Cells were plated in 96-well plates and allowed to adhere overnight.
Subsequently, cells were treated with adenine (A), inosine (I), uracil (U)
and orotate (O), in concentration as shown in parenthesis beneath each bar
(in mM). 5-FU was dissolved in water and added to media at 10 μM.
Media was changed every day with reapplication of 5-FU. After 72 h, the
cell viability was assessed and is expressed relative to the vehicle control.
(Caco-2, n=3). Panel a, asterisks denote significance from respective
control. Panels b-d, bars with different letters are significantly different
from each other (ANOVA, followed by Tukey’smulticomparison test,
p<0.05)
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importance, the region of cell turnover disappears. Thus, a
normal tissue, in which the regions of cell replication and cell
turnover are separated, becomes a dysplastic tissue where all
the epithelial cells replicate in response to the unattentuated
proliferative signals originating from the mesenchymal layer.
The consequence is that all the cells within the epithelial layer
compete progressively for nutrients from the underlying vas-
culature, as they increase in number. This selection pressure, if
sustained, is predicted to cause progressive phenotypic and
genotypic evolution of the epithelial cells, as has been ob-
served for GI glandular cells of the colon [20]. This oncogenic
process may result in a breach by the epithelial cell of the
basement membrane and EMT (epithelial mesenchymal trans-
formation) in the competition for nutrients.
Support for this model of tissue growth, with a reversed
direction of growth in oncogenesis comes from explanations it
provides for several currently puzzling clinical and research
observations. First, H. Pylori is a bacterial infection that in-
volves the glycocalyx or superior aspect of gastric columnar
cells [21]. Perhaps, surprisinglyH. Pylori infection can lead to
cancer. However, this bacterium uses glucose as a nutrient
source and thus infection by H. Pylori may cause a local
nutrient stress to the underlying glandular cells and result in
a tissue with a reversed direction of growth and an increased
cancer risk.
Second, the esophagus and the colon are much more likely
than the small bowel to undergo epithelial cell oncogenesis.
The present model would suggest that this could result from
Fig. 5 NDGP in normal and dysplastic GI squamous and glandular cells
and 5-FU metabolism in normal cells. Shown in the top panels are the
predominant pathways of 5-FU metabolism. In normal oral squamous
cells salvage pathways dominate and uracil competes with 5-FU for
metabolism by UPP1/TYMP. In normal GI glandular mucosa, de novo
synthesis pathways dominate and excess exogenous adenine relatively
depletes PRPP though metabolism by APRT and makes it rate limiting
for UMPS and favors the lower Km orotate substrate over 5FU. The
lower panels represent the source of nutrients and areas of cellular
replication in both normal and dysplastic tissues. Labels: A, Zone of
cell turnover; B, Zone of replication; C, muscularis mucosa layer; D,
Mesenchymal layer; E, Blood vessel. White arrows depict route of
cellular migration. The nutrient gradient is depicted with shading within
the image, with darker shading representing higher levels of nutrients.
The drawings are based on photographs of pathologic slides. The
panels depicting dysplastic tissues ignore nutrient gradients that would
originate from blood vessels in the tissue either above or below the plane
of the photographed, thin pathologic specimen
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the fact that more nutrients are available and absorbed by the
glandular enterocytes of the small bowel than either the squa-
mous cells of the esophagus or the columnar colonic epithelial
cells [22].
Third, although both portend increased risk of cancer, com-
plete intestinal metaplasia (fully enabled absorptive
enterocytes with villous projections) of the stomach is less
likely than incomplete metaplasia of the esophagus to lead
to epithelial cell cancer [23]. Incomplete metaplasia demon-
strates a histologic pattern with goblet cells like that of the
distal ileum not like that of the adjacent stomach. Consistent
with nutrient stress as the cause of the increased cancer risk
from incomplete metaplasia, normal squamous cells of the
esophagus have a doubling time of 21 days, normal columnar
cells of the stomach 12 days and normal columnar cells of the
ileum only 4 to 5 days [24]. In addition the stomach, in con-
trast to the esophagus, is normally bathed in a high nutrient
content mixture that would tend to mitigate nutrient stress
[25].
The cellular mechanism that directs cell growth under
nutrient stress within the GI tissue is not fully under-
stood, although autophagy is believed to play an impor-
tant role. Autophagy is currently the process of delivery
of cellular cargo via the autophagasome for lysosomal
degradation. Autophagy thus acts as a cellular survival
mechanism under conditions of stress. Autophagy main-
tains cellular integrity by regenerating metabolic precur-
sors and clearing subcellular debris [26, 27]. We postu-
late autophagy may also have an apparently paradoxic,
vital role in maintaining tissue integrity by either
restricting cell turnover or catalyzing cell turnover de-
pending upon nutrient adequacy. Such a role for autoph-
agy is consistent with the activity of coiled-coil myosin-
like BCL2-interacting protein (Beclin-1). Beclin-1 (atg-
6) activates autophagosome formation. When doubly de-
leted in mice, Beclin-1 results in an abnormal ectoder-
mal layer and early embryonic lethality [27]. A role for
autophagy in maintaining tissue structure is evident in
the requirement for autophagy in order to have proper
salivary gland degradation in Drosophila [28].
The control of cell degradation by autophagy in the pres-
ence of nutrient adequacy may involve regulation of Beclin-1
through abrogation of Bcl-2/Bcl-Xl inhibition by both c-jun
N-terminal kinase-1 (JNK-1) [29] and death associated protein
kinase (DAPK) autophagic pathways. DAPK phosphorylates
Beclin-1 itself with constitutive activation of autophagy and
cell death in contrast to JNK1 phosphorylation of Bcl-2/Bcl-
Xl [30]. As cells of GI glandular histology approach the top of
the crypts, the expression of DAPK increases [30]. Cells of
both normal GI squamous and glandular histology express
Beclin-1. Beclin-1 expression is increased in podocytes at
crypt tops by exposure to high glucose levels [30]. Beclin-1
expression decreases with progressive dysplasia [31].
Evidence for related nutrient-responsive systems that func-
tion in the normal region of cell turnover exists. In GI glandu-
lar cells, the cell detachment process is likely mediated by
Ephrin ligand that is sensitive to high glucose levels, in con-
trast to Eph receptor in the replication zone at the crypt base
that is sensitive to low glucose states [32]. High glucose levels
induce bone morphogenic protein-2 (BMP-2) [33]. BMP in-
hibits intestinal stem cell activation and promotes intestinal
cell differentiation at the top of the colonic crypt [18].
As we did with the directed application of a tissue appro-
priate nucleobase to prevent 5FU toxicity, it may be reason-
able to test if restoring an adequate nutrient level at the normal
tissue zone of turnover would also restore normal direction of
cell growth and tissue autophagic function. The intervention
would consist of the directed application of nutrient mix (like-
ly including glucose) to the tissue surface of dysplastic tissues
(prior, normal region of cell turnover). Monitoring the resto-
ration of normal, upregulated Beclin-1 expression may be a
means to follow the efficacy of the intervention.
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